Page 52 - 2019_06-Haematologica-web

E. Lucchini et al.
66. Feng R, Liu X, Zhao Y, et al. GPIIb/IIIa autoantibody predicts better rituximab response in ITP. Br J Haematol. 2018;182 (2):305-307.
67. Nieswandt B, Bergmeier W, Rackebrandt K, Gessner JE, Zirngibl H. Identification of crit- ical antigen-specific mechanisms in the development of immune thrombocytopenic purpura in mice. Blood. 2000;96(7):2520- 2527.
68. Medeot M, Zaja F, Vianelli N, et al. Rituximab therapy in adult patients with relapsed or refractory immune thrombocy-
topenic purpura : long-term follow-up results. Eur J Haematol. 2008;81(3):165-169.
69. Zaja F, Baccarani M, Mazza P, et al. Dexamethasone plus rituximab yields high- er sustained response rates than dexametha- sone monotherapy in adults with primary immune thrombocytopenia. Blood. 2010; 115 (14):2755-2762.
70. Gudbrandsdottir S, Birgens HS, Frederiksen H, et al. Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia. Blood. 2013;121(11): 1976-1981.
71. Choi PY, Roncolato F, Badoux X, et al. A novel triple therapy for ITP using high-dose dexamethasone, low-dose rituximab, and cyclosporine (TT4). Blood. 2015;126(4):500- 503.
72. Li Y, Wang YY, Fei HR, Wang L, Yuan CL. Efficacy of low-dose rituximab in combina- tion with recombinant human thrombopoi- etin in treating ITP. Eur Rev Med Pharmacol Sci. 2015;19(9):1583-1588.
73. Zhou H, Xu M, Qin P, et al. A multicenter randomized open-label study of rituximab plus rhTPO vs rituximab in corticosteroid- resistant or relapsed ITP. Blood. 2015;125(10):1541-1547.
74. Gómez-Almaguer D, Colugna-Pedraza PR, Gómez-De León A, et al. Eltrombopag, low- dose rituximab, and dexamethasone combi- nation as frontline treatment of newly diag- nosed immune thrombocytopaenia. Br J Haematol. 2019;184(2):288-290.
75. Hasan A, Michel M, Patel V, et al. Repeated courses of rituximab in chronic ITP: three different regimens. Am J Hematol. 2009;84 (10):661-665.
76. Giagounidis AA, Anhuf J, Schneider P, et al. Treatment of relapsed idiopathic thrombo- cytopenic purpura with the anti-CD20 mon- oclonal antibody rituximab: a pilot study. Eur J Haematol. 2002;69(2):95-100.
77. Reboursiere E, Fouques H, Maigne G, et al. Rituximab salvage therapy in adults with immune thrombocytopenia: retrospective study on efficacy and safety profiles. Int J Hematol. (2016);104(1):85-91.
78. Garcia-Chavez J, Majluf-Cruz A, Montiel- Cervantes L, Esparza MG, Vela-Ojeda J, Rituximab therapy for chonic and refractory immune thrombocytopenic purpura: a long- term follow-up analysis. Ann Hematol. 2007;86(12):871-877.
79. Rai MP, Lee E, Bussel JB. Rituximab (Ritux) Maintenance infusions in immune thrombo- cytopenia ( ITP ) to prolong remission fol- lowing relapse after initial ritux induction but responded to a second course. Blood. 2018;132(Suppl 1):3753.
80. Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54(2):613-620.
81. Audia S, Samson M, Janikashvili N, et al. Immunologic effects of rituximab on the human spleen in immune thrombocytope-
nia. Blood. 2011;118(16):4394-43400.
82. Stasi R, Del Poeta G, Stipa E, et al. Response to B-cell-depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic
purpura. Blood. 2007;110(8):2924-2930.
83. Stasi R, Cooper N, Del Poeta G, et al. Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell depleting therapy with rituximab. Blood. 2008;112(4):1147-
1150.
84. Gudbrandsdottir S, Brimnes M, Køllgaard T,
Hasselbalch HC, Nielsen CH. Effects of rit- uximab and dexamethasone on regulatory and proinflammatory B-cell subsets in patients with primary immune thrombocy- topenia. Eur J Haematol. 2018;100(1):45-52.
85. Audia S, Samson M, Mahévas M, et al. Preferential splenic CD8+T-cell activation in rituximab-nonresponder patients with immune thrombocytopenia. Blood. 2013;122(14):2477-2486.
86. Guo L, Kapur R, Aslam R, et al. CD20+B-cell depletion therapy suppresses murine CD8+T-cell-mediated immune thrombocy- topenia. Blood. 2016;127(6):735-738.
87. Bao W, Bussel JB, Heck S, et al. Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents. Blood. 2010;116(22):4639-4645.
88. Guo C, Chu X, Shi Y, et al. Correction of Th1-dominant cytokine profiles by high- dose dexamethasone in patients with chron- ic idiopathic thrombocytopenic purpura. J Clin Immunol. 2007;27(6):557-562.
89. LiJ,WangZ,HuS,ZhaoX,CaoL. Correction of abnormal T cell subsets by high-dose dexamethasone in patients with chronic idiopathic thrombocytopenic pur- pura. Immunol Lett. 2013;154(1-2):42-48.
90. Schifferli A, Kühne T. Thrombopoietin receptor agonists: a new immune modulato- ry strategy in immune thrombocytopenia? Semin Hematol. 2016;53 (Suppl 1):S31-34.
91. Mahévas M, Patin P, Huetz F, et al. B cell depletion in immune thrombocytopenia reveals splenic long-lived plasma cells. J Clin Invest. 2013;123(1):432-442.
92. Karmacharya P, Poudel DR, Pathak R, et al. Rituximab-induced serum sickness: a sys- tematic review. Semin Arthritis Rheum. 2015;45(3):334-340.
93. Kumar A, Khamkar K, Gopal H. Serum sick- ness and severe angioedema following ritux- imab therapy in RA. Int J Rheum Dis. 2012;15(1):e6-7.
94. Edwards JC, Cambridge G, Leandro MJ. B cell depletion therapy in rheumatic disease. Best Pract Res Clin Rheumatol. 2006;20 (5):915-928.
95. Diwakar L, Gorrie S, Richter A, et al. Does rituximab aggravate pre-existing hypogam- maglobulinaemia? J Clin Pathol. 2010;63(3): 275-277.
96. Levy R, Mahévas M, Galicier L, et al. Profound symptomatic hypogammaglobu- linemia: a rare late complication after ritux- imab treatment for immune thrombocy- topenia. Report of 3 cases and systematic review of the literature. Autoimmun Rev. 2014;13(10):1055-1063.
97. Michel M, Chanet V, Galicier L, et al. Autoimmune thrombocytopenic purpura and common variable immunodeficiency: analysis of 21 cases and review of the litera- ture. Medicine (Baltimore) (2004);83(4):254- 263.
98. Cooper N, Arnold D. M. The effect of ritux- imab on humoral and cell mediated immu- nity and infection in the treatment of
autoimmune diseases. Br J Haematol.
2010;149(1):3-13.
99. Kado R, Sanders G, McCune WJ. Diagnostic
and therapeutic considerations in patients with hypogammaglobulinemia after ritux- imab therapy. Curr Opin Rheumatol. 2017;29(3):228-233.
100. Gobert D, Bussel JB, Cunningham-Rundles C, et al. Efficacy and safety of rituximab in common variable immunodeficiency-associ- ated immune cytopenias: a retrospective multicentre study on 33 patients. Br J Haematol. 2011;155(4):498-508.
101. Calabrese LH, Molloy ES, Huang D, Ransohoff RM. Progressive multifocal leukoencephalopathy in rheumatic diseases: evolving clinical and pathologic patterns of disease. Arthritis Rheum. 2007;56(7):2116- 2128.
102. Chugh S, Darvish-Kazem S, Lim W, et al. Rituximab plus standard of care for treat- ment of primary immune thrombocytope- nia: a systematic review and meta-analysis. Lancet Haematol. 2015;2(2):e75-81.
103. Nazi I, Kelton JG, Larché M, et al. The effect of rituximab on vaccine responses in patients with immune thrombocytopenia. Blood. 2013;122(11):1946-1953.
104. Cho CH, Hwang WL, Cheng SB, Lee TY, Teng CL. Hepatitis B reactivation induced by rituximab maintenance therapy for lym- phoma. Ann Hematol. 2011;90(1):111-112.
105.Sabath BF, Major EO. Traffic of JC virus from sites of initial infection to the brain: the path to progressive multifocal leukoen- cephalopathy. J Infect Dis. 2002;186 (Suppl 2):S180-186.
106. Bohra C, Sokol L, Dalia S. Progressive multi- focal leukoencephalopathy and monoclonal antibodies: a review. Cancer Control. 2017;24(4):1073274817729901
107. Henegar CE, Eudy AM, Kharat V, Hill DD, Bennett D, Haight B. Progressive multifocal leukoencephalopathy in patients with sys- temic lupus erythematosus: a systematic lit- erature review. Lupus. 2016;25(6):617-626.
108.Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood. 2009;113(20):4834- 4840.
109.Berger JR, Malik V, Lacey S, Brunetta P, Lehane PB. Progressive multifocal leukoen- cephalopathy in rituximab-treated rheumat- ic diseases: a rare event. J Neurovirol. 2018;24(3):323-331.
110. Grant C, Wilson WH, Dunleavy K. Neutropenia associated with rituximab ther- apy. Curr Opin Hematol. 2011;18(1):49-54.
111. Monaco WE, Jones JD, Rigby WF. Rituximab associated late-onset neutropenia-a rheuma- tology case series and review of the litera- ture. Clin Rheumatol. 2016;35(10):2457- 2462.
112.Knight A, Sundstrom Y, Borjesson O, et al. Late-onset neutropenia after rituximab in ANCA-associated vasculitis. Scand J Rheumatol. 2016;45(5):404-407.
113. Moore DC. Drug-Induced Neutropenia: A focus on rituximab-induced late-onset neu- tropenia. P T. 2016;41(12):765-768.
114. Van Vollenhoven RF, Fleischmann RM, Furst DE, Lacey S, Lehane PB. Longterm safety of rituximab: final report of the rheumatoid arthritis global clinical trial program over 11 years. J Rheumatol. 2015;42(10):1761-1766.
115. Fleury I, Chevret S, Pfreundschuh M, et al. Rituximab and risk of second primary malig- nancies in patients with non-Hodgkin lym- phoma: a systematic review and meta-
1134
haematologica | 2019; 104(6)